Allergy drug dupilumab tested as potential hair loss treatment
NCT ID NCT05551793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dupilumab, a drug used for allergies and eczema, can help regrow hair in people with moderate-to-severe alopecia areata who also have allergies or high IgE levels. Participants receive weekly injections of dupilumab or a placebo for 48 weeks, followed by an additional 48 weeks of dupilumab for all. The main goal is to measure changes in scalp hair loss using the SALT score.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab
What this could lead to
If successful, dupilumab could offer a new treatment option for people with alopecia areata who also have allergies or high IgE levels.
What could go wrong
This is a Phase 2 trial with a small number of participants. The drug may not work for everyone, and side effects like injection reactions or eye inflammation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UR Dermatology at College Town
RECRUITINGRochester, New York, 14620, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, Irvine
RECRUITINGIrvine, California, 92697, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact